Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

BACKGROUND: Acute myeloid leukemia (AML) is a life-threatening malignancy with limited treatment options in chemotherapy-refractory patients. A first-in-human dose study was designed to investigate a safe and biologically effective dose range for LY2457546, a novel multikinase inhibitor, in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wacheck, Volker, Lahn, Michael, Dickinson, Gemma, Füreder, Wolfgang, Meyer, Renata, Herndlhofer, Susanne, Füreder, Thorsten, Dorfner, Georg, Pillay, Sada, André, Valérie, Burkholder, Timothy P, Akunda, Jacqueline K, Flye-Blakemore, Leann, Van Bockstaele, Dirk, Schlenk, Richard F, Sperr, Wolfgang R, Valent, Peter
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101112/
https://www.ncbi.nlm.nih.gov/pubmed/21625399
http://dx.doi.org/10.2147/CMR.S19341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101112/
https://www.ncbi.nlm.nih.gov/pubmed/21625399
http://dx.doi.org/10.2147/CMR.S19341

Ejemplares similares